ArticleCancer chemotherapy and pharmacology2026
Post-transplantation gilteritinib maintenance therapy and therapeutic drug monitoring in pediatric acute myeloid leukemia with FLT3-internal tandem duplication.
Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFLT3 internal tandem duplication (FLT3-ITD) mutations occur frequently in acute myeloid leukemia (AML) and are associated with high relapse risk. Post-transplant gilteritinib (GILT) maintenance is effective in adults, but pediatric dosing, safety, and the role of therapeutic drug monitoring (TDM) remain undefined. This study evaluated the safety, efficacy, and pharmacokinetic variability of GILT in pediatric FLT3-ITD AML, focusing on the relationship between trough concentrations and clinical outcomes.
methodsWe retrospectively reviewed three pediatric FLT3-ITD AML patients who received post-hematopoietic cell transplantation (HCT) GILT at our institution. Trough plasma concentrations were measured using liquid chromatography–tandem mass spectrometry and correlated with adverse events and remission status.
resultsA 7-year-old girl developed thrombocytopenia and renal dysfunction at a trough concentration of 372 ng/mL; reduced dosing (20–25 mg/day) stabilized levels at 50–60 ng/mL and was tolerated, with sustained remission at three years post-HCT. A 14-year-old girl developed thrombocytopenia at 179 ng/mL and creatine kinase elevation at 205 ng/mL but remained in remission for three years with dose modification and continuation at 40 mg/day. A 17-year-old boy tolerated 40 mg/day with troughs of 112–162 ng/mL, experiencing only transient, exercise-related creatine kinase elevation, and remains in remission on therapy.
conclusionThese cases highlight inter-individual variability in GILT pharmacokinetics and exposure-related toxicities in children. Adverse events correlated with elevated trough concentrations, while levels near or below 100 ng/mL were generally safe. TDM-guided dosing may enable uninterrupted therapy and optimize safety and efficacy of post-transplant GILT maintenance in pediatric FLT3-ITD AML.
Indexed as
Identifiers
41554949What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.